Archive: Company News
ImmunOs Therapeutics Appoints Claudia Berger as SVP Clinical Development
– Strengthened clinical development expertise to ensure smooth transition into the clinic
Schlieren (Zurich Area), Switzerland. ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that Claudia Berger has been appointed as Senior Vice President Clinical Development, further strengthening the Company’s clinical development and operations expertise as it prepares for initial clinical trials.
BellaSeno Receives Australian Public Grant Totaling AUD 1 Million
— Winner of the Australian Global Innovation Linkages Program
— Funding dedicated to advancing regenerative scaffolds for breast reconstruction and large bone defects
— BellaSeno to lead consortium of renowned commercial and academic partners
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that its Australian subsidiary BellaSeno Pty Ltd has been granted AUD 1 million (EUR 625,600) for the development of regenerative scaffolds for breast reconstruction and large bone defects. The grant was provided under the Australian Global Innovation Linkages Program, which is dedicated to help Australian businesses and researchers collaborate with global partners.
ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board
– Company prepares for further growth and entry into clinical development
– Prof. Andrew Scott, Dmitriy Zamarin, MD, PhD, Prof. Dr. med. Dirk Jäger, and Jeffrey M. Bockman, PhD, appointed as clinical advisors
– Prof. Paul Bowness further strengthens Scientific Advisory Board
ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer. In addition, the Company announced the establishment of a Clinical Advisory Board and the further expansion of its Scientific Advisory Board, reflecting the Company´s recent progress with its preclinical pipeline programs and ongoing preparations for the start of clinical trials.
Omnix Medical Receives NIH Grant for the Development of its Novel Antimicrobial Peptide OMN6
— Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB)
— Clinical trial preparations of OMN6 under way
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has received a grant by the U.S. National Institutes of Health (NIH) for the development of its first-in-class antimicrobial peptide OMN6 targeting Acinetobacter baumannii (AB). Acinetobacter baumannii are multi-drug resistant (MDR) bacteria and designated number one on the WHO/CDC Global Priority Pathogens List.